OmniPathology Attends Pathology Visions 2025 Conference in San Diego
Dr. Mohammad Kamal, CEO of OmniPathology, and Dr. Ronald Blum, Vice President of Science & Technology at OmniPathology, attended the opening day of Pathology Visions 2025 in San Diego, themed “From Pixels to Patients.” The conference highlighted the expanding role of digital technologies in transforming pathology practice and healthcare delivery.
Katrina Logemann, Digital Pathology Imaging Specialist for Leica Biosystems, and Chris Maisano, Solutions Architect for Leica Biosystems, met with Dr. Ronald Blum, Vice President of Science & Technology for OmniPathology to discuss the latest innovations in high-throughput, high-resolution digital pathology scanners. These systems are designed to enhance diagnostic precision and accelerate workfl ow efficiency in pathology laboratories.
OmniPathology was proud to attend Pathology Visions 2025, the Digital Pathology Association’s (DPA) annual convention, where leaders in pathology, technology, and research gathered to explore the future of digital pathology and artificial intelligence.
San Diego, CA, October 5–7, 2025 – OmniPathology’s Dr. Mohammad Kamal, CEO, and Dr. Ronald Blum, Vice President of Science & Technology, attended Pathology Visions 2025, hosted by the Digital Pathology Association (DPA) at the Manchester Grand Hyatt in San Diego, California. This year marked the conference’s largest attendance in the organization’s 15-year history, with more than 1,100 participants from around the world.
Founded in 2009, the DPA brings together over 4,000 healthcare visionaries worldwide, including pathologists, scientists, technologists, laboratorians, researchers, and industry leaders, united in their mission to enhance patient care through innovations in digital pathology and AI.
During the event, Dr. Kamal and Dr. Blum met with industry experts to discuss advancements that are revolutionizing diagnostic workflows and improving patient outcomes through digital integration and artificial intelligence.
OmniPathology remains dedicated to embracing emerging technologies that enhance diagnostic capabilities and patient care. Participation in industry-leading conferences such as Pathology Visions 2025 refl ects the organization’s ongoing commitment to innovation, collaboration, and excellence in pathology.
Learn more about OmniPathology’s commitment to innovation at www.omnipathology.com.
Mark Frushone, Director of Global Business Development for Digital Pathology at Leica Biosystems, met with Dr. Ronald Blum, Vice President of Science & Technology for OmniPathology, to discuss the revolutionary impact of Leica’s digital pathology solutions and their role in advancing global healthcare innovation.
Dr. Ronald Blum, Vice President of Science & Technology at OmniPathology, participated in Pathology Visions 2025 at the Manchester Grand Hyatt, engaging with digital pathology and AI experts to explore the latest breakthroughs in diagnostic imaging and data analytics.
Charles Best, Product Director, Digital Solutions at Gestalt Diagnostics, Dr. Ronald Blum, Vice President of Science & Technology for OmniPathology, and Bruce Gleamza, Sales Director for Gestalt Diagnostics, discussed the latest AI-powered technologies transforming healthcare by enabling clinicians to diagnose diseases more rapidly and accurately.
